Compare Heron Therapeutics Inc (HRTX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Zscaler Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Zscaler Inc trades at $149.44 (market cap $24.23B). The key difference: Zscaler Inc is far larger — about 264.9× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| HRTX | ZS | |
|---|---|---|
Market Cap | $91.46M | $24.23B |
Sector | Health | Technology |
52-Week High | $1.96 | $336.27 |
52-Week Low | $0.39 | $118.05 |
Enterprise Value | $189.36M | $22.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Zscaler (ZS) trades at $150.70, up 0.54% with a bullish technical outlook. The stock shows strong revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings consistently beat expectations, and analyst consensus is strongly bullish with a $192.46 price target. However, the company faces class action investigations and rising AI infrastructure costs that pressure margins.
ZS presents a growth opportunity in cybersecurity with Zero Trust adoption and AI security traction, but investors must weigh persistent losses against high valuation multiples. The stock's 34% YTD decline creates potential upside if execution improves, though competitive pressures and profitability concerns remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
